Current status of proton therapy techniques for lung cancer

Han, Youngyih

doi:10.3857/roj.2019.00633

Cited by 46 publications

(36 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the technical aspects, 88.7% of the patients in the present study received pencil beam scanning proton therapy. IMPT, which is based on the scanning beam technique, is expected to further improve the rate of normal organ sparing [ 19 ]. The treatment outcomes following IMPT re-irradiation were recently published [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer

et al. 2021

View full text Add to dashboard Cite

Purpose This study aimed to evaluate the clinical outcomes and toxicities of salvage proton beam therapy (PBT) in patients with locoregional recurrent non-small cell lung cancer (NSCLC). Materials and Methods We retrospectively reviewed 53 patients who received salvage PBT for locoregionally recurrent NSCLC between January 2016 and December 2019. The median clinical target volume (CTV) was 71.2 cm 3 (range, 13.3 to 1,200.7 cm 3 ). The median prescribed dose was 64.0 cobalt gray equivalent (CGE) (range, 45.0 to 70.0 CGE). One-third of the patients (32.1%) received concurrent chemoradiotherapy (CCRT). Results The patients’ median age was 67 years (range, 44 to 86 years). The initial treatments were surgery in 31 (58.5%), definitive CCRT in 12 (22.6%), and definitive radiotherapy in 10 (18.9%) patients. The median disease-free interval (DFI) was 14 months (range, 3 to 112 months). Thirty-seven patients (69.8%) had a previous radiotherapy history. Among them, 18 patients (48.7%) had in-field recurrence. The median follow-up time after salvage PBT was 15.0 months (range, 3.5 to 49.3 months). During the follow-up period, 26 patients (49.1%) experienced disease progression: local in 13 (24.5%), regional in 14 (26.5%), and distant metastases in 15 (26.5%). The 2-year overall survival (OS) rate, local control rate, and progression-free survival rate were 79.2%, 68.2%, and 37.1%, respectively. Shorter DFI (≤12 months; p = 0.015) and larger CTV (>80 mL; p = 0.014) were associated with poor OS. Grade 3 toxicities occurred in 8 patients (15.1%): esophagitis in 2, dermatitis in 3, and pulmonary toxicities in 4. Conclusion Salvage PBT for locoregionally recurrent NSCLC was effective, and treatment-related toxicities were tolerable.

show abstract

Section: Discussionmentioning

confidence: 99%

Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For these clinical sites, advanced methods, such as MC simulations, can be beneficial. 188 MC calculations are also preferred over ADCs for dose calculations with IMPT systems degrading energy in the nozzle.…”

Section: A3 Accuracy and Limitations Of Analytical Dose Algorithmsmentioning

confidence: 99%

“…For complex geometries such as in head and neck and lung, approximations in ADC and its limited ability in modeling multiple‐Coulomb scattering can lead to geometric miss from overestimating the range or predicting unrealistic dose homogeneity caused by underestimation or overestimation of scatting effects in tissue. For these clinical sites, advanced methods, such as MC simulations, can be beneficial 188 . MC calculations are also preferred over ADCs for dose calculations with IMPT systems degrading energy in the nozzle.…”

Section: Radiotherapy Planning System Commissioningmentioning

confidence: 99%

Clinical commissioning of intensity‐modulated proton therapy systems: Report of AAPM Task Group 185

Farr¹,

Moyers²,

Allgower

et al. 2020

Medical Physics

View full text Add to dashboard Cite

Proton therapy is an expanding radiotherapy modality in the United States and worldwide. With the number of proton therapy centers treating patients increasing, so does the need for consistent, high-quality clinical commissioning practices. Clinical commissioning encompasses the entire proton therapy system's multiple components, including the treatment delivery system, the patient positioning system, and the image-guided radiotherapy components. Also included in the commissioning process are the x-ray computed tomography scanner calibration for proton stopping power, the radiotherapy treatment planning system, and corresponding portions of the treatment management system. This commissioning report focuses exclusively on intensitymodulated scanning systems, presenting details of how to perform the commissioning of the proton therapy and ancillary systems, including the required proton beam measurements, treatment planning system dose modeling, and the equipment needed.

show abstract

“…With the rapid introduction and widespread usage of particle therapy, epidemiologically frequent tumors have been explored. The number of patients treated with proton therapy per year increased from 16,200 in 2015 to approximately 190,000 in 2018 and is expected to grow to be over 300,000 by 2030 (6). In 2014, Bush et al (7) reported the outcomes of proton therapy (PT) on 100 patients diagnosed with invasive non-lobular carcinoma and a maximal tumor dimension of 3 cm.…”

Section: Clinical Outcomes For Proton Therapymentioning

confidence: 99%

Particle Therapy for Breast Cancer: Benefits and Challenges

et al. 2021

View full text Add to dashboard Cite

Hadron therapy with protons and carbon ions is widely attracting interest as a potential competitor of conventional photon radiotherapy. Exquisite dose distribution of charged particles allows for a higher local control of the tumor and lower probability of damage to nearby healthy tissues. Heavy ions have presumed biological advantages rising from their high-linear energy transfer (LET) characteristics, including greater cell-killing effectiveness and reduced heterogeneity dependence of radiation response. Although these advantages are clear and supported by data, only 18.0% of proton and carbon ion radiotherapy (CIRT) facilities in Europe are treating breast cancers. This review summarizes the physical and radiobiological properties of charged particles, clinical use of particle beam for breast cancer, and suggested approaches to overcome technical and financial challenges.

show abstract

Current status of proton therapy techniques for lung cancer

Cited by 46 publications

References 92 publications

Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer

Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer

Clinical commissioning of intensity‐modulated proton therapy systems: Report of AAPM Task Group 185

Particle Therapy for Breast Cancer: Benefits and Challenges

Contact Info

Product

Resources

About